Ralph Wurster, DO
Family Medicine · San Angelo, TXNPI 1962535617
Payments from drug & device makers
Across 271 payments — averaging $16.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Novo Nordisk$990
- AstraZeneca$552
- Boehringer Ingelheim$447
- Lilly USA, LLC$258
- Amgen$177
- plus $1K from 22 others
What the payments were for
- Food & beverage$4,504100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 68 | $1,063 |
| Novo Nordisk | 60 | $990 |
| AstraZeneca | 33 | $552 |
| Boehringer Ingelheim | 24 | $447 |
| Lilly USA, LLC | 13 | $258 |
| Amgen | 23 | $177 |
| GSK | 9 | $163 |
| Bayer | 5 | $118 |
| Pfizer | 6 | $117 |
| Ardelyx, Inc. | 3 | $74 |
| Genentech USA, Inc. | 4 | $71 |
| Exact Sciences | 3 | $64 |
| Verona Pharma, Inc. | 2 | $61 |
| Otsuka America Pharmaceutical, Inc. | 3 | $57 |
| Mannkind Corporation | 2 | $40 |
| Dynavax Technologies Corporation | 1 | $34 |
| Abbott | 1 | $26 |
| Lundbeck LLC | 1 | $26 |
| Astellas Pharma US Inc | 1 | $22 |
| SPR Therapeutics, Inc | 1 | $22 |
| Dexcom, Inc. | 1 | $20 |
| Mylan Specialty L.p. | 1 | $18 |
| Axsome Therapeutics, Inc. | 1 | $17 |
| Paratek Pharmaceuticals, Inc. | 1 | $15 |
| Supernus Pharmaceuticals, Inc. | 1 | $14 |
| BTG International Inc. | 1 | $13 |
| Merck | 1 | $13 |
| Phathom Pharmaceuticals, Inc. | 1 | $12 |
How this compares
$4,504 in reported general payments places this provider in the 85th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 195 | $227,270 |
| JardianceEmpagliflozin | 189 | $207,488 |
| FarxigaDapagliflozin Propanediol | 148 | $142,859 |
| MounjaroTirzepatide | 84 | $114,808 |
| EliquisApixaban | 130 | $113,995 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 111 | $83,120 |
| RybelsusSemaglutide | 45 | $80,081 |
| LinzessLinaclotide | 58 | $59,009 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 63 | $40,962 |
| KerendiaFinerenone | 28 | $31,243 |
| JanuviaSitagliptin Phosphate | 30 | $29,553 |
| Nurtec OdtRimegepant Sulfate | 13 | $25,561 |
| Topiramate ErTopiramate | 24 | $23,422 |
| MyrbetriqMirabegron | 33 | $21,971 |
| VascepaIcosapent Ethyl | 40 | $21,846 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $990 | $307,351240 claims |
| Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat | $447 | $235,206219 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Brilinta, Symbicort | $552 | $203,503251 claims |
| PfizerEliquis, Nurtec Odt | $117 | $139,556143 claims |
| Lilly USA, LLCMounjaro, Trulicity | $258 | $129,48498 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $163 | $97,517143 claims |
| AbbVieLinzess, Vraylar, Ubrelvy | $1,063 | $89,26780 claims |
| BayerKerendia | $118 | $31,24328 claims |
| MerckJanuvia | $13 | $29,55330 claims |
| Astellas Pharma US IncMyrbetriq | $22 | $21,97133 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,760 family medicine providers in Texas.
Other family medicine in San Angelo
- Darrell HerringtonSan Angelo$8M
- Douglas DenhamSan Antonio$68.5M
- Vicki MillerPasadena$58.3M
- Hareshkumar BogharaDesoto$30.3M
- Earl MartinTomball$30.1M
- Lisa HollowayHouston$30.1M
- William SegerFort Worth$27.5M
- Veronica FragosoHouston$24.5M
- Joel SolisMcAllen$21.1M
- George AtieeSan Antonio$19.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.